News

Kaenon Polarized announced a distribution partnership with optical manufacturer Rodenstock of Munich, Germany.

The multimodal anti-allergy agent epinastine hydrochloride 0.05% (Elestat, Inspire Pharmaceuticals) is an ideal treatment option for the management of seasonal allergic conjunctivitis and is a particularly good choice in patients who have dry eye disease as a comorbidity, according to Laurie D. Barber, MD

Jeffrey B. Kindler, chief executive officer and chairman of the board of Pfizer Inc., received the Glaucoma Research Foundation Catalyst Award.

Anti-vascular endothelial growth factor (VEGF) treatments for neovascular age-related macular degeneration represent the most significant advance in ophthalmology over the past decade, according to 52% of respondents to an online survey of members of the American Academy of Ophthalmology conducted in December.

Reichert Inc. has restructured its marketing function in an effort ?to meet the growing demands of the company?s vast product portfolio and improve performance through better focus and accountability,? according to Jerry C. Cirino, chairman and chief executive officer.

The Wilmer Eye Institute, Johns Hopkins University School of Medicine, has established a collaboration with the King Khaled Eye Specialist Hospital in Riyadh, Saudi Arabia.

Fera Pharmaceuticals is now shipping erythromycin and bacitracin ophthalmic ointments.

Alcon Laboratories is purchasing rights in the United States for two FDA-approved topical eye care products, difluprednate ophthalmic emulsion 0.05% (Durezol) and ganciclovir ophthalmic gel 0.15% (Zirgan), from Sirion Therapeutics Inc.

Ophthalmologists, ophthalmic organizations, and companies operating in the ophthalmology arena are contributing to efforts to assist Haiti respond to and recover from the earthquake that occurred in January.

Grid laser photocoagulation remains standard of care for eyes with ME secondary to BRVO.

John T. Flynn, MD, credits those who have contributed to the understanding of retinopathy of prematurity in the past, are currently active, and whose work is laying the groundwork for future breakthroughts.

Findings from recent studies indicate fundus autofluorescence imaging has useful diagnostic and prognostic applications in the clinical management of age-related macular degeneration.

In the future, clinicians may be able to offer patients with central serous retinopathy effective and safe treatment with micropulse laser trabeculoplasty.

New non-invasive imaging modalities are showing promise for enabling earlier detection of hydroxychloroquine retinopathy compared with current recommended screening techniques.

Surgeons who understand vitrectomy fluidics will be better able to maintain intraoperative control and be successful in removing vitreous without tearing the retina.

Many approaches for treating exudative age-related macular degeneration (AMD) have been developed.

An updated analysis of data from an ongoing phase II study of intravitreal ranibizumab treatment for diabetic macular edema shows that functional and anatomic benefits observed at 6-month primary efficacy endpoint are generally maintained at 1 year after switching to a "prn" dosing schedule.

Preferential hyperacuity perimetry testing may be helpful in detection of retinal toxicity resulting from administration of hydroxychloroquine or chloroquine.

A few years ago, I reached the age that men reach when they can no longer eat whatever they want and stay the same weight and remain fit.

A preliminary study of epimacular brachytherapy showed that radiation and antivascular endothelial growth factor injections reduced the treatment burden in patients with neovascular age-related macular degeneration.

Alcon Laboratories' Independent Director Committee is calling Novartis' merger proposal "grossly inadequate," and it is vowing to fight Novartis in its efforts to take control.

A single sustained-release dexamethasone intravitreal implant resulted in resolution of inflammation and improvement in visual acuity (VA) in patients with intermediate or posterior uveitis through 26 weeks in a multicenter, randomized, controlled clinical trial.

Inadequate nutrition is a modifiable risk factor for age-related macular degeneration.

Pooled results from two randomized, investigator-masked parallel group clinical trials show that the fixed combination fo brimonidine tartrate 0.2%-timolol maleate 0.5% produced greater IOP lowering than the fixed combination of dorzolamidehydrochloride 2%-timolol maleate 0.5%, whether the fixed combination products were used alone or as an adjunct to treatment with a prostaglandin analogue.

Timolol maleate 0.5%/sorbitol complex is a convenient, well-tolerated choice for adjunctive therapy in patients taking a prostaglandin analogue who need further IOP control.

Good physicians can serve their patients best by adopting behaviors that might be different from their normal attributes in the rest of their lives.

Switching to another prostaglandin analogue that does not contain benzalkonium chloride may not be the answer for managing complaints from patients of dryness and irritation.

TLC Vision Corp. has won U.S. bankruptcy court approval for a restructuring of its debt.

A handheld applanation tonometer is a newer portable device for measuring IOP that has been designed for reliable performance and easy, economical use.

In response to an FDA warning of cleaning validation at one of its plants, Abbott Medical Optics said problematic manufacturing processes were restricted to production of its ophthalmic viscosurgical device, 3% sodium hyaluronate, which is no longer being made or sold.